stoxline Quote Chart Rank Option Currency Glossary
  
Arcellx, Inc. (ACLX)
67.59  -3.36 (-4.74%)    07-18 16:00
Open: 71.29
High: 71.36
Volume: 517,576
  
Pre. Close: 70.95
Low: 66.93
Market Cap: 3,725(M)
Technical analysis
2025-07-18 4:38:56 PM
Short term     
Mid term     
Targets 6-month :  83.52 1-year :  97.55
Resists First :  71.51 Second :  83.52
Pivot price 67.7
Supports First :  64.96 Second :  60.91
MAs MA(5) :  69.46 MA(20) :  66.72
MA(100) :  64.57 MA(250) :  71.33
MACD MACD :  1.4 Signal :  1.2
%K %D K(14,3) :  81.5 D(3) :  84.5
RSI RSI(14): 52.5
52-week High :  107.37 Low :  47.86
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ ACLX ] has closed above bottom band by 48.4%. Bollinger Bands are 33.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 71.44 - 71.82 71.82 - 72.14
Low: 66.07 - 66.48 66.48 - 66.83
Close: 66.92 - 67.61 67.61 - 68.21
Company Description

Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.

Headline News

Thu, 17 Jul 2025
There's Reason For Concern Over Arcellx, Inc.'s (NASDAQ:ACLX) Price - 富途牛牛

Thu, 17 Jul 2025
Arcellx Advances Phase 3 Study for Multiple Myeloma Treatment - TipRanks

Tue, 15 Jul 2025
Arcellx; Anito-Cel With D-Domain Differentiation Looks To Capture R/R MM Market (ACLX) - Seeking Alpha

Fri, 11 Jul 2025
We're Not Very Worried About Arcellx's (NASDAQ:ACLX) Cash Burn Rate - simplywall.st

Wed, 09 Jul 2025
How might ACLX's 2025 Q1 EPS forecast affect strategies? - AInvest

Tue, 20 May 2025
Analysts Offer Insights on Healthcare Companies: Centessa Pharmaceuticals (CNTA), Arcellx Inc (ACLX) and Belite Bio, Inc. ADR (BLTE) - The Globe and Mail

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 55 (M)
Shares Float 33 (M)
Held by Insiders 14.5 (%)
Held by Institutions 102 (%)
Shares Short 6,240 (K)
Shares Short P.Month 7,130 (K)
Stock Financials
EPS -3
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 7.57
Profit Margin -211.5 %
Operating Margin -847.6 %
Return on Assets (ttm) -16.7 %
Return on Equity (ttm) -35.6 %
Qtrly Rev. Growth -79.4 %
Gross Profit (p.s.) -1.8
Sales Per Share 1.39
EBITDA (p.s.) -3.36
Qtrly Earnings Growth 0 %
Operating Cash Flow -115 (M)
Levered Free Cash Flow -10 (M)
Stock Valuations
PE Ratio -22.61
PEG Ratio 0
Price to Book value 8.92
Price to Sales 48.49
Price to Cash Flow -32.48
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android